An observational study in Obstructive Lung Diseases, Respiratory Symptoms and Inflammation, sponsored by Sykehuset Telemark. Recruiting at 1 site in Norway. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sykehuset Telemark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Respiratory conditions impose an enormous burden on the individual and the society. According to the WHO World Health Report 2000, the top five respiratory diseases - including asthma and COPD - account for 17% of all deaths and 13% of all Disability-Adjusted Life Years (DALYs). Obstructive lung diseases are among the most common chronic diseases in working-aged populations affecting \~40 million individuals in Europe. The greatest economic burden of respiratory diseases on health services and lost production in the EU is due to COPD and asthma, at about €20 billion each for healthcare and €25 billion and €15 billion, respectively, for lost production.
For Norway, there are no estimates of asthma prevalence for the country as a whole, but 80/1000 women and 55/1000 men used asthma medication in 2013 according to the national prescription register. Estimated annual deaths in Norway due to COPD were 4070 in 2015, which is 30% higher than for lung cancer. Unfortunately, a substantial proportion of patients are still difficult to treat. This underlines the need for better primary prevention and more knowledge regarding causes and exacerbating factors.
Several risk factors for chronic respiratory diseases are identified, most important tobacco smoke, closely followed by air pollution and occupational exposure. However, according to recent reviews there is a lack of understanding regarding environmental risk factors and mechanisms of how these affect respiratory health, the importance of biological markers and comorbidity, and of socioeconomic risk factors. Moreover, there is a need for assessment of interactions between risk factors and between the individual and the environment.
Telemark has a high proportion of craft- and industrial workers providing exposure contrasts. Furthermore, the use of medication against respiratory diseases and the rate of sick leave are higher in Telemark than elsewhere in Norway. Moreover, the county has a high rate of disability. There are previous studies from other parts of Norway, which have estimated the occurrence of respiratory diseases and provided valuable knowledge regarding some risk factors. However, these studies use crude measures of self-reported exposure and do not provide sufficient information on how to target intervention and implement effective prevention. In contrast to the Telemark study, these studies have not included register data or advanced modelling of environmental exposure.
Hypotheses and choice of methods:
Primary objective:
To identify preventive and health promoting measures for obstructive respiratory disease in a 5-year follow up of adults from the general population in Telemark.
Secondary objectives:
Research problems/questions (Q):
Q1 What are the emerging occupational risk factors for respiratory health? Q2 What are the social inequity/socioeconomic factors predicting respiratory disease? Q3 How does HRQoL develop over time? Q4 Do risk factors interact and how do they relate to the individual? Q5 What is the population attributable risk (PAR) for the identified risk factors, and what are the key factors for better prevention and respiratory health promotion?
Choice of methods/work packages (WP) and approaches (A):
WP I Occupational risk factors Q1 Emerging occupational causes and risk factors for respiratory disease and exacerbation
WP II Individual risk factors Q2 Risk factors for social inequity in respiratory health
WP III Complex interactions Q3 Health related quality of life development over time.
202 studies on the registry are indexed under Lung Diseases, Obstructive; 23 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 185 across 48 observational studies indexed under Lung Diseases, Obstructive.
Browse Lung Diseases, Obstructive studies →Sykehuset Telemark is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The researchers collected data in 2013 on respiratory symptoms and physician diagnosed asthma from 16.099 inhabitants of Telemark County (the cross-sectional baseline study called The Telemark-study I). A random sample from the baseline study of approximately 650 asthma cases and 650 controls were asked to take part in a medical examination in a case-control study in 2014-15.
The five year follow up of the baseline (The Telemark-study II) study was performed in 2018 and included 13500 subjects. The follow-up of the nested case-control study started in September 2018 and is on-going.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The occurence of asthma and the association to specific occupational and environmental exposures and comorbidity
Incidence and associations
Time frame: Five years
Risk factors for the occurence of asthma symptoms in subjects with asthma symptoms but no asthma diagnosis
Odds ratio
Time frame: Five years
Differences in lung function, FeNO and inflammatory markers in blood in asthma patients and the association of these changes to specific occupational and environmental exposures.
Lung function indices, serum levels in blood
Time frame: Five years
Plan to share: Undecided
Started Feb 2018 (actual). Primary completion is estimated for Jan 2035, 203 months after the start.
Of 25 observational studies under Lung Diseases, Obstructive, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 203 months is above that.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2035 → Jan 2035, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sykehuset Telemark